Bank of New York Mellon Corp Sells 4,071 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Bank of New York Mellon Corp decreased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIOFree Report) by 1.9% in the third quarter, Holdings Channel.com reports. The firm owned 205,875 shares of the biopharmaceutical company’s stock after selling 4,071 shares during the period. Bank of New York Mellon Corp’s holdings in Agios Pharmaceuticals were worth $5,095,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. raised its holdings in Agios Pharmaceuticals by 9.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,587 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 387 shares during the last quarter. American International Group Inc. raised its holdings in Agios Pharmaceuticals by 1.5% in the 2nd quarter. American International Group Inc. now owns 26,736 shares of the biopharmaceutical company’s stock worth $757,000 after acquiring an additional 396 shares during the last quarter. Great West Life Assurance Co. Can raised its holdings in Agios Pharmaceuticals by 2.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 25,483 shares of the biopharmaceutical company’s stock worth $586,000 after acquiring an additional 550 shares during the last quarter. ProShare Advisors LLC raised its holdings in Agios Pharmaceuticals by 5.5% in the 2nd quarter. ProShare Advisors LLC now owns 10,821 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 565 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Agios Pharmaceuticals by 1.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 47,604 shares of the biopharmaceutical company’s stock worth $1,348,000 after acquiring an additional 590 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AGIO shares. The Goldman Sachs Group decreased their price objective on shares of Agios Pharmaceuticals from $32.00 to $28.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. StockNews.com began coverage on shares of Agios Pharmaceuticals in a research note on Thursday, October 5th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $35.20.

View Our Latest Stock Analysis on Agios Pharmaceuticals

Agios Pharmaceuticals Trading Down 1.0 %

Shares of AGIO opened at $22.62 on Thursday. Agios Pharmaceuticals, Inc. has a 1-year low of $19.80 and a 1-year high of $31.50. The firm has a fifty day simple moving average of $22.74 and a two-hundred day simple moving average of $23.98. The firm has a market cap of $1.26 billion, a PE ratio of -5.73 and a beta of 0.81.

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.05. Agios Pharmaceuticals had a negative net margin of 913.95% and a negative return on equity of 22.03%. The firm had revenue of $7.40 million during the quarter, compared to the consensus estimate of $7.73 million. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.25 EPS for the current fiscal year.

Insider Activity

In other news, insider James William Burns sold 1,163 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $22.99, for a total transaction of $26,737.37. Following the completion of the sale, the insider now owns 26,336 shares of the company’s stock, valued at approximately $605,464.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, insider James William Burns sold 1,163 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $22.99, for a total value of $26,737.37. Following the completion of the transaction, the insider now owns 26,336 shares of the company’s stock, valued at approximately $605,464.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tsveta Milanova sold 2,902 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $22.32, for a total transaction of $64,772.64. Following the completion of the transaction, the insider now directly owns 9,404 shares of the company’s stock, valued at approximately $209,897.28. The disclosure for this sale can be found here. Insiders sold a total of 46,473 shares of company stock valued at $1,036,836 in the last 90 days. Company insiders own 4.24% of the company’s stock.

Agios Pharmaceuticals Company Profile

(Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias.

Read More

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIOFree Report).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.